NCT01114230View on ClinicalTrials.gov

A First in Man Study to Determine the Safety at Various Dose Levels of AGS-16M8F in Advanced Kidney Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

August 31, 2010

Primary Completion Date

November 30, 2012

Study Completion Date

November 30, 2012

Conditions
Renal Cell CarcinomaPharmacokinetics of AGS-16M8F
Interventions
DRUG

AGS-16M8F

IV

Trial Locations (3)

10021

Memorial Sloan Kettering Cancer Center, New York

98109

Seattle Cancer Care Alliance, Seattle

02115

Dana-Farber Cancer Institute, Boston

Sponsors

Collaborators (1)

Agensys, Inc.
All Listed Sponsors
collaborator

Agensys, Inc.

INDUSTRY

lead

Astellas Pharma Inc

INDUSTRY